Progress has been made under the national pharmaceutical strategy, and the provinces and territories are working on their own priorities. I'll use one example in the Atlantic provinces, where there is a bulk purchasing by three jurisdictions to address some of those types of challenges.
We continue to work with provinces and territories to address our common interest, and the federal government is part of that. We're a huge purchaser of this as well, for first nations health, and we are making progress in increasing access to a number of drug therapies for our population.
In terms of one plan for every jurisdiction, it's not that easy. Each jurisdiction has tackled the national pharmaceutical strategy collectively—British Columbia, Alberta, and Saskatchewan being one, the Atlantic provinces being another, and Ontario is examining with Quebec as well.
So there are different steps being undertaken by jurisdictions that deliver health care and have primary responsibility for these programs.